Searching over 5,500,000 cases.

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.


January 7, 2004.


The opinion of the court was delivered by: JAMES ZAGEL, District Judge


Plaintiff Sirius Laboratories, Inc. filed suit against Defendant Rising Pharmaceuticals, Inc. alleging violations of the Lanham Act, 15 U.S.C. § 1125(a), the Illinois Consumer Fraud Act, 815 ILCS 505/1 et seq., and the Illinois Deceptive Trade Practices Act, 815 ILCS 510/1 et seq. The statements alleged to be false are the product name "Anthralin Cream 1% USP" and its placement on the product's box, tubing, packaging inserts, price list and submission of data to First Data Bank, a trade organization. Rising moves to dismiss all claims pursuant to Federal Rule of Civil Procedure 12(b)(6). A claim may be dismissed either because it asserts a legal theory that is not cognizable as a matter of law or because it fails to allege sufficient facts to support a cognizable legal claim. In ruling on a motion to dismiss, I must presume that all allegations contained in the Complaint are true, and resolve all doubt and inferences in favor of Sirius. See Albright v. Oliver, 510 U.S. 266, 267 (1994).

Factual Background

  From February 2001 until late 2002, Sirius was the sole distributor of an anthralin cream 1% United States Pharmacopia (USP) prescription medicine for the treatment of psoriasis. At Page 2 some point, Rising began offering a lower-cost substitute anthralin cream product which it named and labeled "Anthralin Cream 1% USP." Sirius alleges that this product actually contains less than 1%, as defined under the governing USP standard which requires a product to contain 90.50-115.00% of the labeled strength. The USP — a not-for-profit organization funded through the contributions of pharmacy, medicine and other health care professionals, as well as academia, the federal government and consumer organizations — is entrusted by the Food and Drug Administration (FDA) with establishing standards that ensure the quality of medicines and other health care technologies. FDA regulations not only recognize and incorporate the USP standards, 21 U.S.C. § 321(j), but also look to it to define what constitutes a drug, 21 U.S.C. § 321(g)(1).

 Preclusion of Lanham Act Claim by Food, Drug And Cosmetic Act

  In its Lanham Act claim, Sirius alleges that Rising's product is misbranded and falsely labeled because it contains less than anthralin cream 1% USP as defined under the USP specification. Under § 43(a) of the Lanham Act, a party has a private cause of action for misrepresentation and false description of any goods, including pharmaceuticals. 15 U.S.C. § 1125(a); Genderm Corp. v. Biozone Labs., No. 92 C 2533, 1992 WL 220638, at *12 (N.D. Ill. Sept. 3, 1992). One limitation exists for claims brought under the Lanham Act. "[C]ourts have held not only that a plaintiff may not seek to enforce directly the [Food, Drug and Cosmetic Act, 21 C.F.R. § 146.135 et seq. (FDCA)] through the Lanham Act but also that a plaintiff may not maintain a Lanham Act claim if the claim requires direct application or interpretation of the FDCA or FDA regulations." Healthpoint, Ltd. v. Ethex Corp., 273 F. Supp.2d 817, 837 (W.D. Page 3 Tex. 2001) (collecting cases). "[S]uch a claim would allow a private litigant to interfere with the PDA's own investigatory time-table and prosecutorial decision-making [and] would force the Court to rule directly `on the legality of . . . conduct before the FDA has had a chance to do so.'" Summit Tech., Inc. v. High-Line Med. Instruments, Co., 933 F. Supp. 918, 932 (C.D. Cal. 1996) ("Summit II") (quoting Summit Tech., Inc. v. High-Line Med. Instruments Company, Inc., 922 F. Supp. 299, 306 (C.D. Cal. 1996) ("Summit I"). The District Court should not "determine presumptively how a federal agency will interpret and enforce its own regulations." Summit II, 933 F. Supp. at 932 (quoting Sandoz Pharm. Corp. v. Richardson-Vicks, Inc., 902 F.2d 222, 223 (3rd Cir. 1990) (citations omitted); see Dial A Car, Inc. v. Transp., Inc., 82 F.3d 484, 490 (D.C. Cir. 1996) (Lanham Act cannot be used as a "back-door method" of interpreting and enforcing administrative regulations). "To do so would violate Congressional intent that the FDA have discretion to enforce the FDCA and implementing regulations." Healthpoint, 273 F. Supp.2d at 837 (citing United States v. Goodman, 486 F.2d 847, 855 (7th Cir. 1973)).

  In this case, Rising argues that Sirius' Lanham Act claim should be dismissed because the issue of whether a product is adulterated or misbranded under FDA standards is an issue within the exclusive purview of the FDCA and thus not properly decided in a Lanham Act case. According to the FDCA, a drug or device is misbranded "if its labeling is false or misleading in any particular." 21 U.S.C. § 351(a). A drug is adulterated if it is represented as a drug of the name of which is recognized in an official compendium (such as the USP), and its strength differs from, or its quality or purity falls below, the standard set forth in such compendium. Such determination as to strength, quality, or purity shall be made in accordance with the tests or Page 4 methods of assay set forth in such compendium. 21 U.S.C. § 351(b). Congress has formally recognized the USP as an official compendium. 21 U.S.C. § 321(j).

  Unfortunately, "[t]here is no single, bright-line test to distinguish sustainable from non-sustainable claims." Healthpoint, 273 F. Supp.2d at 837. Perhaps as a result, therefore, some courts have held that certain false statements are actionable under the Lanham Act "even if their truth may be generally within the purview of the FDA." Summit II, 933 F. Supp. at 933; see Mylan Labs., Inc. v. Matkari, 7 F.3d 1130, 1138 (4th Cir. 1993); Summit II, 933 F. Supp. at 933; Grove Fresh Distribs., Inc. v. Flavor Fresh Foods, Inc., 720 F. Supp. 714, 716 (N.D. Ill. 1989) ("Grove Fresh I"); Grove Fresh Distribs., Inc. v. Everfresh Juice Co., No. 89 C 1113, 89 C 1117, 89 C 1118, 1989 WL 152670 (N.D. Ill. Nov. 29, 1989) ("Grove Fresh II"). Of course, the two most relevant cases for purposes of a case in the Northern District of Illinois such as the present one are Grove Fresh I and II.

  In Grove Fresh I, a plaintiff alleged that because defendant's orange juice contained additives and adulterants, the representation that the product was "100% orange juice from concentrate" was false. 720 F. Supp. at 716. The district court denied the defendant's motion to dismiss the Lanham Act claim, holding that it was not an impermissible attempt to recover damages for the misbranding of food in violation of the FDCA:

  Grove Fresh relies on the FDA regulation [that defines "orange juice from concentrate"] merely to establish the standard or duty which defendants allegedly failed to meet. Nothing prohibits Grove Fresh from using the FDCA or its accompanying regulations in that fashion. . . . Grove Fresh does not base its claim solely on the FDCA or FDA regulations. Grove Fresh alleges that defendants have violated section 43(a) of the Lanham Act. Even without the FDA regulation defining "orange juice from concentrate," Grove Fresh could attempt to establish a violation of section 43(a). Grove Fresh would simply need to provide other evidence establishing the proper market definition of "orange juice from concentrate." Page 5

 Id. at 716. The Court allowed plaintiff to bring a Lanham Act cause of action for affirmatively misrepresenting facts — whether the orange juice was "pure" under a commercial definition — without interpreting any FDA regulation.

  Two months later, I reached roughly the same conclusion in Grove Fresh II. In that case, I held that "[w]here Congress has precluded private causes of action under the FDCA, [I] find it difficult to justify the use of the FDCA to establish a crucial element of a private cause of action under the Lanham Act." Grove Fresh II, 1989 WL 152670, at *3. Therefore, I prohibited plaintiff from arguing that defendants' products did not meet FDCA standards to establish a crucial element of its Lanham Act claim because this would have been "very substantial use of the FDCA." Id. To sustain its claim, the plaintiff would have to "provide other evidence establishing the proper market definition of `orange juice from concentrate.'" Id.

  In contrast to the Grove Fresh cases, consideration of Sirius' Lanham Act claim would not require me to interpret the FDCA or any of its accompanying regulations. First, Sirius is simply relying on the USP definition of 1% anthralin cream to establish the standard which Rising failed to meet. This standard is not ambiguous, nor is it subject to interpretation or the exercise of some discretion. Rising's product either meets the USP standard because it contains between 90.50% and 115.00% of the labeled strength of anthralin cream or it does not, and therefore my decision on this issue would not usurp any function otherwise delegated to the FDA. Second, the USP is a not-for-profit organization entrusted by the FDA with establishing standards that ensure the quality of medicines and other health care technologies. Although it arguably performs government functions, the USP is neither part of the government nor of the FDA specifically. And in contrast to rules and regulations promulgated directly by the FDA, the Page 6 standards established by the USP are incorporated by the FDA into its rules and regulations. In other words, ...

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.